The Sensex finished 38 points higher at 3,640 on Thursday. The Nifty closed with a gain of 12 points at 1,146.
The country's drug companies have attracted the highest number of enforcements from the American drug regulator in 2013, a year that has seen the US Food and Drug Administration turning stricter to ensure compliance levels and quality of medicines.
The Sensex closed at new high of 7,211 with a gain of 17 points.
The Sensex staged a smart recovery as it rallied from the day's low of 9897 to a high of 10,093 - up 2% (196 points).
Ranbaxy soared 6.5% to close at Rs 433. Cipla gained 1.6% at Rs 562. Dr.Reddy's, too, was up over 1% at Rs 1,205.
The Sensex closed with a gain of 111 points (1.4%) at 8,318.
The Sensex opened with a good positive gap of 18 points at 4,075. It is now up 21 points at 4,078.
The Sensex opened a tad higher at 5,073 - up six points, and is now at 5,081 - up 14 points.
Mirroring buoyant global markets the Sensex opened with a positive gap of 18 points at 5,056. The index is now at 5,075 - up 37 points. The Nifty is at 1,591, up nine points.
The Sensex opened a point higher at 5,104. The index slipped into negative zone and is now at 5,077 - down 26 points. The Nifty is at 1,597 - down seven points.
Mirroring the gains at Wall Steet and strong Asian markets, the Sensex opened with a positive gap of 11 points at 5,263. It moved up a tad to touch a high of 5,269, before slipping into negative zone owing to profit-taking.
Margaret A Hamburg, the first commissioner of the US Food and Drug Administration (US FDA) to visit India officially, will meet heads of major domestic pharma companies such as Ranbaxy, Wockhardt, Cadila Healthcare and Lupin in New Delhi.
FDI in drugs and pharmaceuticals was $487 million during April-August 2012, according to the latest data of the Department of Industrial Policy and Promotion.
The BSE Sensex opened 9 points higher at 5,713. Continued buying has meant that the indices have moved further upwards. The Sensex is now at 5,734, up 30 points.
The Sensex opened with a positive gap of 11 points at 5,381, it slipped marginally to touch an intra-day low of 5,380.
Today, apologies by CEOs of global corporations have become so common that you get case studies on the subject.
The Sensex closed with a gain of 16 points at 3,780.\n\n\n\n
Sun Pharma profit down 30% over compliance costs, lower sales.
As part of the charm offensive, New Delhi has invited global regulators -- including the FDA -- to visit Indian production units to get first-hand evidence of measures taken to ensure the quality of locally manufactured generics.
A glance back at some of the important ups and down Indian Inc faced in 2018.
The Singapore subsidiary of the UK-based GlaxoSmithKline plans to buy 24.33 per cent stake or 2.06 crore equity shares in GlaxoSmithKline Pharmaceuticals Ltd through an open offer.
The 30-share Sensex ended 50 points lower at 28,112 and the 50-share Nifty declined 12 points to close at 8,531.
Roadblocks ahead as these medicines could face new clinical tests, more scrutiny
.jpg)
The report comes at a time when the government is trying to clear pending FDI proposals, which include various planned investments in this sector.
A global policy would reward firms which strive for higher quality.
Ties between India and the United States have been strained in recent years because of trade policies and patent disputes.
Sachin Bansal, who had co-founded Flipkart with Binny Bansal in 2007, would exit the company
Shanghvi needs to deploy this excess cash.
Competition in the US pharmaceutical market swelled in recent years, with increasing generic penetration.
At 15.05 PM, the 30-share Sensex was up 281 points at 28,238 and the 50-share Nifty gained 86 points at 8,577
Various domestic companies such as Ranbaxy, Wockhardt and Agila Specialities recently came under the US FDA scanner for lapse in manufacturing practices.
Top companies added employees at 3% CAGR from 2003-04 to 2013-14, while revenues grew at 18%.
The news that exports to the US will not restart before next year as well as the September quarter performance are sentiment dampeners.
The FDA has stepped up its efforts to ensure drug safety in recent months.
Industry is gathering scientific data to approach the regulator, DCGI, for a review of the suspension order.
Experts believe market launches can now happen seamlessly and quickly if FSSAI is removed from the process.
At present, there is no direct air connectivity between India and Myanmar.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances